Table 2.
Reasons for Study Drug Discontinuation
| Reason | Rociletinib |
Chemotherapy (n = 74)b | ||
|---|---|---|---|---|
| 500 mg Twice Daily (n = 53)a | 625 mg Twice Daily (n = 22) | Overall (n = 75)a | ||
| Progressive disease | 42 (79.2) | 14 (63.6) | 56 (74.7) | 49 (66.2) |
| AE | 3 (5.7) | 4 (18.2) | 7 (9.3) | 6 (8.1) |
| Patient choice | 1 (1.9) | 1 (4.5) | 2 (2.7) | 6 (8.1) |
| Physician decision | 2 (3.8) | 0 | 2 (2.7) | 5 (6.8) |
| Death (excluding disease progression) | 3 (5.7) | 3 (13.6) | 6 (8.0) | 3 (4.1) |
AE, adverse event.
a
A total of 2 patients discontinued because of study termination.
b
A total of 4 patients discontinued because of other reasons, and one patient had missing data.